DALLAS--(BUSINESS WIRE)--HemoBioTech (OTCBB: HMBT – News, http://www.hemobiotech.com), a developmental biopharmaceutical company focused on developing and commercializing the first viable human blood substitute, has been highlighted in the January 5-11th issue of New Scientist.
